Crescent Biopharma, Inc. Common Stock (CBIO) Stock Price

CBIOStock

$17.00+12.68%52W

Market Cap$631.45M

P/E—

PEG Ratio—

Div yield—

Beta1.27

CBIO Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)63.34%

Price vs S&P 500 (4W)0.17%

VGM Score38.80

Book Value / Share (Quarterly)$5.88

P/TBV (Annual)1.76x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)413.69%

Cash Flow / Share (Quarterly)$-5.53

Price vs S&P 500 (YTD)31.13%

Net Profit Margin (TTM)-990.32%

EPS (TTM)$-7.41

10-Day Avg Trading Volume0.16M

EPS Excl Extra (TTM)$-7.41

Revenue Growth (5Y)1.31%

EPS (Annual)$-14.97

ROI (Annual)-76.81%

Gross Margin (Annual)-0.50%

Net Profit Margin (5Y Avg)-86953.02%

Cash / Share (Quarterly)$6.18

ROA (Last FY)-64.90%

EBITD / Share (TTM)$-6.78

ROE (5Y Avg)-214.46%

Operating Margin (TTM)-978.04%

Cash Flow / Share (Annual)$-5.24

P/B Ratio3.78x

P/B Ratio (Quarterly)3.04x

Net Income / Employee (Annual)$-3,544,100

EV / Revenue (TTM)37.54x

ROA (TTM)-87.91%

EPS Incl Extra (Annual)$-14.97

Current Ratio (Annual)6.56x

Quick Ratio (Quarterly)9.26x

3-Month Avg Trading Volume0.32M

52-Week Price Return12.68%

Revenue / Employee (TTM)$270,100

Tangible BV / Share (Quarterly)$0.13

P/S Ratio (Annual)56.96x

Asset Turnover (Annual)0.05x

52-Week High$27.41

Operating Margin (5Y Avg)-91877.45%

EPS Excl Extra (Annual)$-14.97

CapEx CAGR (5Y)301.37%

Tangible BV CAGR (5Y)-17.70%

26-Week Price Return74.59%

Quick Ratio (Annual)6.41x

13-Week Price Return-16.11%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)9.66x

Enterprise Value$446.11M

Revenue / Share Growth (5Y)36.20%

Asset Turnover (TTM)0.05x

Book Value / Share Growth (5Y)15.76%

Revenue / Employee (Annual)$246,500

Pretax Margin (Annual)-1401.16%

Cash / Share (Annual)$7.74

3-Month Return Std Dev72.54%

Net Income / Employee (TTM)$-3,798,300

ROE (Last FY)-76.81%

EPS Basic Excl Extra (Annual)$-14.97

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-7.41

Receivables Turnover (Annual)0.23x

ROI (TTM)-100.26%

P/S Ratio (TTM)51.98x

Pretax Margin (5Y Avg)-86945.64%

Revenue / Share (Annual)$1.04

Tangible BV / Share (Annual)$0.31

Price vs S&P 500 (52W)-5.63%

Year-to-Date Return43.09%

5-Day Price Return1.68%

EPS Normalized (Annual)$-14.97

ROA (5Y Avg)-129.05%

Net Profit Margin (Annual)-1438.05%

Month-to-Date Return17.28%

Cash Flow / Share (TTM)$-1.37

EBITD / Share (Annual)$-14.65

Operating Margin (Annual)-1407.52%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-214.46%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-7.41

P/TBV (Quarterly)4.10x

P/B Ratio (Annual)0.81x

Pretax Margin (TTM)-956.66%

Book Value / Share (Annual)$7.37

Price vs S&P 500 (13W)-18.91%

Beta1.27x

P/FCF (Annual)45.19x

Revenue / Share (TTM)$0.39

ROE (TTM)-100.26%

52-Week Low$8.72

vGradeD

gGradeD

mGradeC

vgmGradeD

CBIO Earnings Surprise History

Q2 25-3.72est. -3.68

Q3 25-1.37est. -1.39

Q4 25-4.92est. -2.82

Q1 26-0.70est. -0.79

Q2 26-0.62est. -0.64

CBIO Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.33

4.27

Industry Peers — Pharmaceuticals(571)

Symbol	Value Score	Growth Score	Momentum Score	Price
CBIOCrescent Biopharma, Inc. Common Stock	D	D	C	$17.00
LLYEli Lilly & Co.	D	B	B	$1233.66
JNJJohnson & Johnson	D	C	B	$273.14
ABBVABBVIE INC.	D	C	B	$265.79
MRKMerck & Co., Inc.	D	C	A	$156.45
NVSNovartis AG	C	C	C	$159.98
AZNAstraZeneca PLC	C	B	C	$169.66
NVONovo-Nordisk A/S	B	C	C	$48.66
ABTAbbott Laboratories	C	C	B	$116.13
PFEPfizer Inc.	C	D	C	$28.57
VRTXVertex Pharmaceuticals Inc	D	C	B	$552.85
BMYBristol-Myers Squibb Co.	B	B	B	$67.92
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$46.02
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$52.07
REGNRegeneron Pharmaceuticals Inc	C	C	B	$833.56
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	C	$18.35
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$38.10
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	C	$376.37
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$62.07
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$240.08
ZTSZOETIS INC.	B	C	D	$77.29
INSMInsmed, Inc.	F	A	C	$123.89
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$36.47
UTHRUnited Therapeutics Corp	C	C	C	$518.53
GMABGenmab A/S ADS	C	C	B	$34.36
VTRSViatris Inc. Common Stock	B	C	B	$16.72
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$260.23
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$252.99
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$80.40
CORTCorcept Therapeutics Inc.	F	C	A	$123.57
BMRNBioMarin Pharmaceuticals Inc	C	C	C	$66.12
ARWRArrowhead Research Corporation	D	A	B	$88.88
ELANElanco Animal Health Incorporated Common Stock	C	B	B	$25.09
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	$512.16
CYTKCytokinetics Inc.	F	D	B	$77.46
AXSMAxsome Therapeutics, Inc	D	B	C	$205.48
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.36
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$63.57
ABVXAbivax SA American Depositary Shares	—	—	C	$117.93
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.34
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$368.02
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PTGXProtagonist Therapeutics, Inc	F	B	A	$150.59
SYRESpyre Therapeutics, Inc. Common Stock	—	—	A	$107.36
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.86
TGTXTG Therapeutics, Inc.	D	B	A	$55.42
ALKSAlkermes Inc. plc	D	C	B	$49.21
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$113.35
ORKAOruka Therapeutics, Inc. Common Stock	F	—	A	$101.82
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	$161.68
COGTCogent Biosciences, Inc. Common Stock	F	—	B	$36.80

About Crescent Biopharma, Inc. Common Stock

Crescent Biopharma develops novel therapeutics for solid tumors, with CR-001, a bispecific antibody targeting PD-1 and VEGF designed to improve upon existing immunotherapy options. CR-001 is modeled after ivonescimab, which demonstrated superior efficacy versus Keytruda in Phase 3 testing for non-small cell lung cancer. The company is also advancing CR-002 and CR-003, antibody-drug conjugate programs targeting validated oncology indications.